Rapport Therapeutics' (RAPP) RAP-219 is Best-in-Class - Citizens

December 8, 2025 4:37 AM EST Send to a Friend
Citizens analyst Jason Butler reiterated a Market Outperform rating and $80.00 price target on Rapport Therapeutics (NASDAQ: RAPP).The analyst commented ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE

Member Login